Sionna Therapeutics (NASDAQ:SION) Lowered to Hold Rating by JonesTrading

Sionna Therapeutics (NASDAQ:SION) was downgraded by research analysts at JonesTrading from a “strong-buy” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

A number of other research analysts have also recently commented on the company. Freedom Capital cut Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 20th. Citigroup lowered Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday. Royal Bank Of Canada upgraded Sionna Therapeutics from an “underperform” rating to a “sector perform” rating and set a $5.00 price objective for the company in a report on Monday. BTIG Research lowered Sionna Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday. Finally, Guggenheim cut Sionna Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday. One investment analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $42.22.

Sionna Therapeutics Price Performance

SION stock opened at $5.10 on Monday. Sionna Therapeutics has a one year low of $4.01 and a one year high of $54.97. The stock has a market cap of $230.58 million, a PE ratio of -2.34 and a beta of 1.32. The firm has a 50 day simple moving average of $40.99 and a two-hundred day simple moving average of $39.92.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.02). On average, research analysts expect that Sionna Therapeutics will post -2.66 EPS for the current fiscal year.

Insider Activity

In other news, Director Peter A. Thompson sold 85,918 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the transaction, the director directly owned 2,469,959 shares of the company’s stock, valued at approximately $110,802,360.74. This trade represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of Sionna Therapeutics stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the transaction, the director owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 403,726 shares of company stock valued at $18,259,354. Company insiders own 5.10% of the company’s stock.

Institutional Trading of Sionna Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Viking Global Investors LP increased its stake in shares of Sionna Therapeutics by 8.2% in the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after buying an additional 242,427 shares during the period. BlackRock Inc. bought a new stake in Sionna Therapeutics during the 2nd quarter valued at $64,875,000. Jennison Associates LLC boosted its position in Sionna Therapeutics by 30.1% during the 1st quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock valued at $58,179,000 after buying an additional 335,942 shares during the period. Vanguard Group Inc. grew its holdings in Sionna Therapeutics by 3.7% in the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock worth $48,749,000 after acquiring an additional 41,797 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in Sionna Therapeutics by 30.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 831,373 shares of the company’s stock worth $34,203,000 after acquiring an additional 193,613 shares during the last quarter.

Key Headlines Impacting Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

• Negative Sentiment: SION-719 failed its Phase 2 primary endpoint. The experimental cystic-fibrosis treatment did not produce the expected improvement, prompting Sionna to discontinue development of SION-719 as an add-on therapy. The failure eliminates the company’s principal near-term clinical catalyst and raises uncertainty about the value of its broader pipeline. Sionna Therapeutics Halts Lead Cystic Fibrosis Drug After Phase 2 Failure
• Negative Sentiment: The stock dropped roughly 90% to a record low. The magnitude of the decline reflects investors’ reassessment of Sionna’s prospects following the unexpected trial miss and the loss of its lead drug program. Trading volume was also unusually heavy compared with the company’s average. Sionna Therapeutics stock falls 92% after SION-719 trial failure
• Negative Sentiment: Analysts cut their ratings after the clinical setback. BTIG and Guggenheim moved from “buy” to “neutral,” while Raymond James, Citizens JMP and Wedbush also reduced their ratings. Wedbush and RBC set approximately $5 price targets, signaling limited expected upside at current levels. Sionna Discontinues Cystic Fibrosis Drug Following Unfavorable Data
• Neutral Sentiment: Sionna reported mixed results from two cystic-fibrosis programs and plans to refocus its pipeline. However, the company has not yet identified a replacement asset with comparable clinical maturity, leaving its future strategy and financing needs uncertain. Sionna Reports Mixed Trial Results and Refocuses CF Pipeline
• Neutral Sentiment: The failure benefits rival Vertex Pharmaceuticals. Sionna’s unsuccessful trial removes a potential competitor to Vertex’s established cystic-fibrosis franchise, which explains why Vertex shares rose as Sionna’s stock declined. Vertex Shares Rise as Rival Sionna Trial Fails

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.